Plutux
Novocure Ltd logo

Novocure Ltd

NVCR
$17.61
-0.17%
2026-09-04 10:41:02 EDT-$0.03
헬스케어
의료 - 기기
NASDAQ
활발히 거래 중

NovoCure Limited는 종양 치료 분야의 기업으로, 미국, 독일, 프랑스, 일본, 그레이터 차이나 및 전 세계에서 고형 종양 암의 치료를 위한 종양 치료 ...

주가 흐름

$17.61
-0.17%-$0.03
고가—
저가—
52주 최고-17.9%
거래량비—
간격
범위65m
거래량—SMA5SMA10
—

회사 개요

NovoCure Limited is a global oncology company focused on developing and commercializing a novel cancer therapy called Tumor Treating Fields (TTFields). The company's primary products are medical devices that deliver TTFields to tumors, designed to disrupt cancer cell division. Their main commercial products include Optune Gio, Optune Lua, and Optune ...NovoCure Limited is a global oncology company focused on developing and commercializing a novel cancer therapy called Tumor Treating Fields (TTFields). The company's primary products are medical devices that deliver TTFields to tumors, designed to disrupt cancer cell division. Their main commercial products include Optune Gio, Optune Lua, and Optune Pax, used for treating glioblastoma, mesothelioma, and other solid tumors. Novocure is headquartered in Baar, Switzerland, and operates in markets across the United States, Europe, Japan, Greater China, and other international regions. The company was founded in 2000 by Prof. Yoram Palti, who discovered the effects of TTFields on cancer cells. As of the most recent data, the company has approximately 1,605 full-time employees. Financially, Novocure is a commercial-stage company with significant revenue, reporting a revenue per share of $6.03, but it has yet to achieve profitability, with a net profit margin of -21.2% and a negative return on equity of -44%. The company's financial ratios indicate a gross profit margin of 76.1%, reflecting strong product margins, but high research and development costs (32.1% of revenue) and SG&A expenses (66.1% of revenue) contribute to operating losses. Novocure continues to invest heavily in clinical trials for brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company's leadership includes CEO Frank Leonard, and it remains committed to extending survival in aggressive cancers through its innovative TTFields technology. With a market capitalization of approximately $1.9 billion, Novocure is a notable player in the medical devices sector, focusing on oncology and aiming to make a significant impact on cancer treatment worldwide.
설립
2000
직원 수
1605
CEO
Frank Leonard
정식 명칭
Novocure Ltd
섹터
헬스케어
산업
의료 - 기기
ROE
-44.00%
시가총액
$2.05B
유동비율
2.89
WACC
8.57%
ROIC
-25.72%

연락처 정보

https://www.novocure.com
44 15 3475 6700
Neuhofstrasse 21, Baar 6340

관련 종목Medical - Devices

전체 미국 주식 보기 →
회사 소개개인정보 처리방침서비스 약관면책 조항종목 디렉터리ETF지수13F 보유 종목목표주가무료 도구기술 지도Slack 참여하기

Plutux는 투자자문업자가 아닙니다. 시장 데이터와 AI가 생성한 분석은 정보 제공 및 교육 목적일 뿐 투자 자문이 아닙니다. 면책 조항

© Plutux Technology Limited 2026